
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is poised for success with a diverse portfolio of assets and promising products in the pipeline, a strong financial position, and strategic investments. Their recent financial results have surpassed expectations, and their hospital-based products are showing strong growth potential. While there may be industry risks, BTIG, LLC values Innoviva favorably using an NPV SOTP analysis, making them a compelling investment opportunity.
Bears say
Innoviva is highly dependent on its Xacduro product, which has shown strong launch ramp and exceeded management's expectations. However, the company's over-reliance on a single product makes it vulnerable to potential resistance and increasing competition in the hospital setting, which could negatively impact its revenue and financial performance. As such, the company's overall financial outlook is uncertain and may have a negative impact on its stock.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares